Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Abstract
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1–based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1–based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding pancreatitis have not been substantiated in large cardiovascular outcome trials (92, 93).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [92]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70-85% of patients and lead to treatment discontinuation [22,38,41,60,61]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [41]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Self-citationEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 1
- Styrkarsdottir, Obesity variants in the GIPR gene do not associate with risk of fracture or bone mineral density, J Clin Endocrinol Metab
Cited by
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4789 · Cited by 287
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“There is considerable interest in expanding the delivery of GLP-1-based medicines beyond peptides, to include small-molecule orally available tablets or capsules, antibodies, gene or cell-based therapy, RNA interference and even gene editing to activate components of GLP-1R signaling pathways 14 .”
InfluentialSelf-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“Concerns regarding pancreatitis have not been substantiated in large cardiovascular outcome trials (92, 93).”
Self-citationExploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
Obesity: Recent Advances and Future Perspectives
Janić, M., Janež, A., El‐Tanani, M., & Rizzo, M. (2025) · Biomedicines · doi:10.3390/biomedicines13020368 · Cited by 97
“The main endpoint encompasses all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and heart failure events that require urgent medical consultations or hospital admissions (NCT05556512) [9].”
InfluentialAyoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 94
“Initially, there was also a concern over the possible increased risk of thyroid cancer associated with GLP-1 RAs, leading the FDA to issue a black box warning for specific agents; however, population-based studies have yielded more mixed results and no causal link has yet been established [23,24].”
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“As the field of GLP-1 medicines expands to encompass molecules targeting additional receptors in new disease indications, it is incumbent on researchers to remain vigilant for new adverse events not previously detected in studies of first-generation GLP-1 therapies 17 .”
Self-citationBae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 104
“Diabetes Metab J 2025;49:386-402 https://e-dmj.org GLP-1 receptor agonists are commonly associated with gastrointestinal adverse events, which may lead to dehydration in some people [112].”
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Klonoff, D. C., Hui, G., & Gombar, S. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241268050 · Cited by 49
Targher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2025) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 48
“11 12 GLP-1 receptors are not expressed in human hepatocytes.”
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 64
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“EXPERT OPINION ON PHARMACOTHERAPY Currently, there are two ongoing phase 3 clinical trials (NCT04777396 and NCT04777409) assessing oral semaglu-tide’s impact on early Alzheimer’s disease [99].”
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“Key drivers identified for reduced adherence to GLP-1RAs are decreasing BMI class (95), and common adverse effects of nausea, emesis, and diarrhea, which affect ∼ 60% of patients (17).”
InfluentialMannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 143
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
The potential role of GLP ‐1 receptor agonists in osteoarthritis
Ryan, M., Megyeri, S., Nuffer, W. A., & Trujillo, J. M. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70005 · Cited by 47
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“The early hypothesis that GLP-1RAs increase the risk of pancreatitis and pancreatic and colorectal cancer appears to be disproven, while data on the enhancement of thyroid carcinoma remain inconclusive [120].”
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
Haberman, R. H., Ogdie, A., Merola, J. F., Scher, J. U., & Eder, L. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01326-6 · Cited by 52
“The emergence of GLP-1-based therapies has introduced a promising pharmacological strategy to address both obesity and the associated state of metabolic inflammation in PsA 229 .”
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
“Liraglutide and dulaglutide generally show better tolerability but still require careful counseling to maintain adherence (Drucker, 2024).”
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
“Among these, dulaglutide, semaglutide, and tirzepatide are the most widely used GLP-1RAs for T2D, with their efficacy supported by robust evidence from phase 3 clinical trials [8, 10].”
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Kouveletsou, M., Kontrafouri, P., Eleftheriadou, I., Diakoumopoulou, E., Karampela, Ι., Tentolouris, N., & Dalamaga, Μ. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00612-4 · Cited by 48
“The emergence of newer pharmacological agents with proven cardiovascular and renal benefits, such as GLP-1 RAs and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, has further diminished the role of TZDs in contemporary T2DM management [15, 16].”
Li, J., Liu, F., Luo, Y., Wijeyesekera, A., Wang, S., Chen, X., Lv, Y., Jin, J., Sheng, H.-F., Wang, G., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04189-6 · Cited by 41
“Various approaches are currently utilized to manage glycemic metabolism and ameliorate metabolic disorders, including pharmacological interventions, dietary control, physical activity, and surgical procedures [2–4].”
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“These necessitate careful patient selection, comprehensive monitoring, and risk mitigation strategies [4,201,202].”
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Guo, H., Yang, J., Huang, J., Xu, L., Lv, Y., Wang, Y., Ren, J., Feng, Y., Zheng, Q., & Li, L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100162 · Cited by 32
“In clinical trials, common adverse reactions to GLP-1 class drugs include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation [30,31].”
Amini, A., Hamann, S., & Larsen, M. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17473 · Cited by 33
“The similarity of semaglutide-related NAION and early worsening of retinopathy suggests that both are un-specific responses to rapid glycaemia reduction and a class effect that may be associated with GLP-1 agonists in general (Drucker, 2024) rather than a specific effect of semaglutide.”
Sagy, Y. W., Ramot, N., Battat, E., Arbel, R., Reges, O., Dicker, D., & Lavie, G. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103213 · Cited by 34
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“This class of drugs is now used widely, with beneficial GLP-1R–mediated effects on body weight and glycemic control, as well as their cardio-renal complications (7, 14).”
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 45
“More recently, higher doses of semaglutide and the co-agonist tirzepatide have shown substantial weight loss efficacy, even among individuals without diabetes, prompting their regulatory approval for chronic weight management in several countries [23, 26].”
Kellett, J., Soliman, S. S., Podwójniak, A., Minkanic, M., Kumar, G., Goodwin, B. J., Yang, H. J., Elsawwah, J. K., & Németh, Z. H. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07723-w · Cited by 31
“Through rapid weight loss and the attenuation of cholecystokinin-stimulated gallbladder emptying, GLP-1 agonists have also been shown to cause cholecystitis, cholelithiasis, and biliary obstruction [33].”
Marassi, M., Cignarella, A., Russo, G. T., Nollino, L., Strazzabosco, M., Marzullo, P., Leonetti, F., Avogaro, A., Consoli, A., & Fadini, G. P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107866 · Cited by 38
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
“Whereas weight loss interventions are intended to reduce adipose tissue, loss of lean mass (including muscle) is common 30 , as are increased bone turnover and decreased bone mineral density (BMD).”
InfluentialKim, T. H., Lee, K., Park, S., Oh, J., Park, J., Jo, H., Lee, H., Cho, J., Wen, X., Cho, H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16376 · Cited by 37
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 58
“The most common adverse effects (AEs) associated with GBTs are GI, mainly nausea, vomiting, diarrhoea and constipation [22,23].”
Torbahn, G., Lischka, J., Brown, T. J., Ells, L. J., Kelly, A. S., Wabitsch, M., & Weghuber, D. (2024) · Clinical Endocrinology · doi:10.1111/cen.15133 · Cited by 34
Kuo, C.-C., Chuang, M., Li, C., Huang, P., Kuo, H., & Lai, C. (2024) · Hepatology International · doi:10.1007/s12072-024-10752-9 · Cited by 28
“GLP-1RAs are a class of medications that mimic the action of the endogenous hormone GLP-1, which plays a crucial role in glucose homeostasis, appetite regulation, and potentially liver health [4, 5, 7, 11].”
Marassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
Kuo, C., Li, C., Chuang, M., Huang, P., Kuo, H., & Lai, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70007 · Cited by 27
Sarcopenic obesity and weight loss-induced muscle mass loss
Caturano, A., Amaro, A., Berra, C., & Conte, C. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001131 · Cited by 75
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
“129 132 The dual agonist telpor similarly exhibits neuroprotective effects by improving energy metabolism and inhibiting inflammatory pathways in PD models.”
Dash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
Price, S., & Nankervis, A. J. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07849-9 · Cited by 32
Heni, M., Frühwald, L., Karges, W., Naudorf, M., Niemöller, K., Pagnia, F., Reindel, J., Seufert, J., Ufer, G., Wagner, C., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06448-w · Cited by 27
Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is used for the management of T2DM and has demonstrated efficacy in controlling obesity, blood pressure, and dyslipidemia, along with exhibiting significant anti-inflammatory effects [30, 31].”
Ahmad, P., Estrin, N. E., Farshidfar, N., Zhang, Y., & Miron, R. J. (2025) · Journal of Periodontal Research · doi:10.1111/jre.13410 · Cited by 32
Rabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide
Pinheiro, M. M., de Souza, L. G., Nunes, G. P., Martin, I. F., de Oliveira, Y. U., Pinheiro, F. M. M., Costa, L. N., Caprio, M., Della‐Morte, D., & Infante, M. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2386047 · Cited by 24
“Semaglutide is a medication approved for the treatment of T2DM, obesity and overweight associated with one or more weight-related comorbidities 27 .”
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 27
Why are we still in need for novel anti-obesity medications?
Novikoff, A., Grandl, G., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101098 · Cited by 22
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
“In line with these results, the European Society of Cardiology guidelines and the American Diabetes Association have recommended the use of GLP-1 RA in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases [76] (Table 1).”
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
“291,318 Evidence is growing that GLP-1RA may represent a therapeutic strategy against Alzheimer and Parkinson disease, fatty liver disease, and peripheral artery disease (atherosclerosis) 281 as well as hypertension (see above) beyond glycemic control and weight loss.”
Li, Z., Han, Z., Sun, R., Xuan, X., & Huang, C. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s539822 · Cited by 23
“14,15 Moreover, a network meta-analysis demonstrated that GLP-1RAs were associated with improvements in insulin resistance and β-cell function, thereby leading to diabetes remission.”
Goldenberg, R., Gilbert, J. D., Houlden, R. L., Khan, T., Makhija, S., Mazer, C. D., Trinacty, J., & Verma, S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2458538 · Cited by 24
“Slowed bowel motility can elevate the risk of ileus or intestinal obstruction and possibly decrease the efficacy of bowel preparation for colonoscopy 8,10–12 .”
Brosnihan, P., Luce, M. S., Yetasook, A. K., Perez, C., Scharf, K. R., & Aly, S. (2025) · The American Surgeon™ · doi:10.1177/00031348251337145 · Cited by 17
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
“…over the last decade, it has become increasingly evident that these medications should not simply be regarded as glucose-lowering and weight loss drugs, as they have been proven to exert significant cardioprotective and nephroprotective actions in patients with T2D and/or overweight/obesity [3–8].”
InfluentialTamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
“The rapid and robust improvements in glycemic control and inflammatory markers, contrasted with the more gradual hepatic structural changes, suggest that therapeutic benefits are mediated through both direct metabolic effects and indirect consequences of improved systemic metabolism [64, 65].”
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Pratley, R. E., Saeed, Z. I., & Casu, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001057 · Cited by 16
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Inoue, K., Saliba, D., Gotanda, H., Moin, T., Mangione, C. M., Klomhaus, A. M., & Tsugawa, Y. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02648 · Cited by 22
Recent Updates on Diabetes and Bone
Brunetti, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178140 · Cited by 14
“Tirzepatide determined substantial weight loss of up to 20% in obese patients without T2D [52].”
Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 17
Self-citationGlucagon-like peptide-1 receptor agonism and end-organ protection
Daniels, S. J., Karlsson, C., Schrauwen, P., & Parker, V. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.002 · Cited by 20
Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus
Dou, X., Zhao, L., Li, J., & Jiang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1537898 · Cited by 19
“Drucker (2024) highlighted that while GLP-1RAs demonstrate significant cardiorenal and metabolic benefits, their widespread use has also been associated with certain psychiatric adverse events, such as nervousness, stress, and eating disorders.”
Lambert, G. W., Patel, M., & Lambert, É. (2025) · Metabolites · doi:10.3390/metabo15050286 · Cited by 15
“An increasing number of GLP-1 agents have been developed and trialled, showing improvement in glucose control and weight reduction [117].”
Miranda, S., Choudhari, J., Chauhan, N., & Parmar, M. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177953 · Cited by 17
GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes
Meron, M. K., Hornik‐Lurie, T., Twig, G., & Rotman‐Pikielny, P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag056 · Cited by 18
Liabeuf, S., Minutolo, R., Floege, J., & Zoccali, C. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae380 · Cited by 21
Characterization and Role of Glucagon-Like Peptide 1 Receptor in the Lacrimal Gland
Sun, Y., Zhang, Y., Shi, F., Li, Y., Wang, C., Yu, F., Chen, T., Xia, D., Xu, Y., Zhao, Y., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.12.003 · Cited by 13
Grosicki, G. J., Thomas, J. G., Dhurandhar, N. V., Lofton, H. F., Heymsfield, S., & Jonnalagadda, S. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16151 · Cited by 12
“20 To support long-term weight loss maintenance in this growing user-group, barriers to continued GLP-1 RA treatment should be addressed through testing strategies such as patient and health insurer education on the chronicity of obesity, the long-term cost-effectiveness of sustained treatment and…”
Peptide-based drugs in immunotherapy: current advances and future prospects
Karati, D., Meur, S., Das, S., Adak, A., & Mukherjee, S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02739-9 · Cited by 14
“Immunogenicity can neutralize therapeutic effects (e.g., insulin analogs) or cause hypersensitivity reactions, as seen with taspoglutide, which was discontinued due to severe allergic responses in Phase III trials [246].”
Thornton, P., Reader, V., Digby, Z., Doedens, J. R., Lindsay, N. A., Clarke, N. P., & Watt, A. P. (2025) · Obesity · doi:10.1002/oby.24305 · Cited by 15
“The introduction of dual agonist drugs such glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor agonists (GLP-1RAs/GIPR) for the treatment of obesity and type 2 diabetes [2] highlights the impressive efficacy that is now achievable [3].”
Incretin-Based Therapies and Cancer: What’s New?
Medenica, S., Bogdanović, J. M., Vekić, J., Vojinović, T., Babić, I., Bogdanovic, L. M., Maggio, V., El‐Tanani, M., & Rizzo, M. (2025) · Medicina · doi:10.3390/medicina61040678 · Cited by 13
“In addition to their glycemic benefits, clinical trials have identified other advantages of incretin-based therapies, including weight reduction and cardiovascular and renal protection in patients with and without T2D, underscoring their potential for broader clinical applications [3–5].”
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo, L., Zhang, B., Xue, X., Zhang, B., Cai, H., Jiang, H., Zhang, L., Jin, P., Wang, X., Cheng, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-10031-z · Cited by 21
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 16
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Triplett, J. D., Pinto, M. V., Young, N. P., Staff, N. P., Marathe, C. S., Horowitz, M., Pinto, C. A., Laughlin, R. S., Shouman, K., Berini, S. E., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213916 · Cited by 18
Glucagon-like peptide-1 medicines and cancer
Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 16
“By contrast, GLP-1R expression is very low or undetectable in normal thyroid C cells from monkeys and humans, and GLP-1 medicines do not stimulate calcitonin secretion or C cell proliferation in humans 19,55 .”
Self-citationYuan, Y., Wang, H., Jiang, Z.-J., Liu, C., Li, Q., Zhou, S.-R., & Yang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01923-z · Cited by 14
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Thermogenic adipose tissues: Promising therapeutic targets for metabolic diseases
Pahlavani, M., Pham, K., Kalupahana, N. S., Morovati, A., Ramalingam, L., Abidi, H., Kiridana, V., & Moustaïd‐Moussa, N. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109832 · Cited by 12
Negative Feedback Loops and Hormonal Factors that Regulate GH Secretion
de Sousa, L. M. M., Vicente, V. V. D. A., & Donato, J. (2025) · Endocrinology · doi:10.1210/endocr/bqaf139 · Cited by 16
Wang, S., Liu, Y., Yan, Z., Huang, X., Liao, Y., Tang, C., Jing, L., Zhou, Z., Han, J. D. J., Tang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02032 · Cited by 10
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Representatives of the GLP-1RA class that are currently approved for glycemic control in T2DM include short-and long-acting exenatide, liraglutide, dulaglutide, lixisenatide, subcutaneous and oral semaglutide, efpeglenatide, and beinaglutide [46–48].”
Lai, S., Kang, Z., Sun, J., Wang, Z., Xu, Y., Xing, S., Feng, M., Wang, Y., & Liu, H. (2025) · Brain Sciences · doi:10.3390/brainsci15050480 · Cited by 9
“Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has been approved to help people with diabetes and obesity [6].”
Huang, Y., Chen, J.-C., Li, P., Hsu, M., Cheng, C., Meyerowitz‐Katz, G., & Su, P. (2025) · Communications Medicine · doi:10.1038/s43856-025-01066-4 · Cited by 11
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 13
Self-citationChakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 12
Zhang, L., Chen, X., Li, J., Hou, Q., Song, J., Fu, X., Liu, Y., Jin, B., Feng, Y., Zhang, W., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147728 · Cited by 13
Sklepinski, S. M., Deng, Y., SWARNA, K. S., Herrin, J. S., Polley, E. C., Neumiller, J. J., Galindo, R. J., Umpierrez, G. E., Ross, J. S., Borah, B. J., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112910 · Cited by 9
Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
Carter, P., Simó, R., Lövestam‐Adrian, M., Pearce, I., Bain, S. C., Dinah, C., Davies, S. J., Strain, W. D., Burgess, P. I., Gamble, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70160 · Cited by 16
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-06-06
- Volume
- 47
- Issue
- 11
- Pages
- 1873-1888
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4399395008
- Semantic Scholar
- 306e8b284bd34405b3e79c99c37f0dec0c95f1ed
- Cited by
- 383
- References
- 171
- Citations by year
- 2026: 176 · 2025: 168 · 2024: 39
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes for Health Research (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, tirzepatide, retatrutide, survodutide, cardiorenal benefits, drug safety, fracture, bone mineral density, muscle strength, gastrointestinal motility, anesthesia, pancreatic diseases, biliary tract diseases, cancer risk, cardiometabolic disease, personalized medicine
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.